|
pubmed:abstractText |
We report a case of a 59-year-old woman with metastatic carcinoma of the ileocecal region who received FOLFOX(oxaliplatin/leucovorin/5-fluorouracil) and bevacizumab therapy and exhibited a partial remission with minimal side effects. She developed a mild self-limited episode of immune-mediated hemolytic anemia during her 16th cycle of chemotherapy, which precluded her from receiving further oxaliplatin. We review the literature on oxaliplatin-induced immune-mediated hemolysis, including its mechanism, presenting symptoms, laboratory features, management, and implications for future therapy.
|
|
pubmed:affiliation |
Mid Valley Oncology/Hematology, P.C., 407 Gidney Avenue, Newburgh, NY 12550, USA. vanita.noronha@gmail.com
|
